Skip to main content

Advertisement

SpringerLink
Log in

Bioequivalence for Topical Products—An Update

  • Expert Review
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

With the exception of topical glucocorticoids, demonstrating bioequivalence between generic and reference topical products entails conducting clinical end-point trials which are both lengthy and expensive. Considerable effort has been channeled towards development and validation of alternative approaches to demonstrate bioequivalence of topical and transdermal products. The critical opportunity pathways identified by the FDA for the industry for topical bioequivalence include the following surrogate methods: in vitro studies, dermatopharmacokinetic method, dermal microdialysis and near infrared spectroscopy. This review provides an update of recent advances in these methodologies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

REFERENCES

  1. OGD. Generic Competition and Drug Prices. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129385.htm (accessed 6/25/2010).

  2. US FDA. Guidance for Industry. Topical dermatologic corticosteroids: In-vivo bioequivalence. Rockville: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 1995.

    Google Scholar 

  3. Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm. 2008;68:453–66.

    Article  CAS  PubMed  Google Scholar 

  4. Pershing LK, Bakhtian S, Poncelet CE, Corlett JL, Shah VP. Comparison of skin stripping, in vitro release, and skin blanching response methods to measure dose response and similarity of triamcinolone acetonide cream strengths from two manufactured sources. J Pharm Sci. 2002;91:1312–23.

    Article  CAS  PubMed  Google Scholar 

  5. Au WL, Skinner M, Kanfer I. Bioequivalence assessment of topical clobetasol propionate products using visual and chromametric assessment of skin blanching. J Pharm Pharm Sci. 2008;11:160–6.

    CAS  PubMed  Google Scholar 

  6. Lionberger RA. FDA critical path initiatives: opportunities for generic drug development. AAPS J. 2008;10:103–9.

    Article  PubMed  Google Scholar 

  7. Muller M, Brunner M, Schmid R, Putz EM, Schmiedberger A, Wallner I, et al. Comparison of three different experimental methods for the assessment of peripheral compartment pharmacokinetics in humans. Life Sci. 1998;62:PL227–34.

    Article  CAS  PubMed  Google Scholar 

  8. Volden G, Thorsrud AK, Bjornson I, Jellum E. Biochemical composition of suction blister fluid determined by high resolution multicomponent analysis (capillary gas chromatography–mass spectrometry and two-dimensional electrophoresis). J Invest Dermatol. 1980;75:421–4.

    Article  CAS  PubMed  Google Scholar 

  9. Svedman P, Svedman C. Skin mini-erosion sampling technique: feasibility study with regard to serial glucose measurement. Pharm Res. 1998;15:883–8.

    Article  CAS  PubMed  Google Scholar 

  10. Schrolnberger C, Brunner M, Mayer BX, Eichler HG, Muller M. Application of the minimal trauma tissue biopsy to transdermal clinical pharmacokinetic studies. J Control Release. 2001;75:297–306.

    Article  CAS  PubMed  Google Scholar 

  11. Treffel P, Makki S, Faivre B, Humbert P, Blanc D, Agache P. Citropten and bergapten suction blister fluid concentrations after solar product application in man. Skin Pharmacol. 1991;4:100–8.

    Article  CAS  PubMed  Google Scholar 

  12. Makki S, Treffel P, Humbert P, Agache P. High-performance liquid chromatographic determination of citropten and bergapten in suction blister fluid after solar product application in humans. J Chromatogr. 1991;563:407–13.

    Article  CAS  PubMed  Google Scholar 

  13. Surber C, Wilhelm KP, Bermann D, Maibach HI. In vivo skin penetration of acitretin in volunteers using three sampling techniques. Pharm Res. 1993;10:1291–4.

    Article  CAS  PubMed  Google Scholar 

  14. Herkenne C, Alberti I, Naik A, Kalia YN, Mathy FX, Preat V, et al. In vivo methods for the assessment of topical drug bioavailability. Pharm Res. 2008;25:87–103.

    Article  CAS  PubMed  Google Scholar 

  15. Zhou X, Liu D, Liu H, Yang Q, Yao K, Wang X, et al. Effect of low molecular weight chitosans on drug permeation through mouse skin: 1. Transdermal delivery of baicalin. J Pharm Sci. 2010;99:2991–8.

    Article  CAS  PubMed  Google Scholar 

  16. Yuan JS, Yip A, Nguyen N, Chu J, Wen XY, Acosta EJ. Effect of surfactant concentration on transdermal lidocaine delivery with linker microemulsions. Int J Pharm. 2010;392:274–84.

    Article  CAS  PubMed  Google Scholar 

  17. Sapra B, Jain S, Tiwary AK. Percutaneous permeation enhancement by terpenes: mechanistic view. AAPS J. 2008;10:120–32.

    Article  CAS  PubMed  Google Scholar 

  18. US FDA. Extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations. Rockville: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 1997.

    Google Scholar 

  19. USP. <1088> In vitro and in vivo evaluation of dosage forms. United States Pharmacopeia 32/National Formulary 27. Rockville: The USP; 2010.

    Google Scholar 

  20. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982.

    Google Scholar 

  21. Shaw JE, Chandrasekaran SK, Michaels AS, Taskovich L. In: Maibach HI, editor. Controlled transdermal delivery, in vitro and in vivo. New York: Churchill-Livingstone; 1975. p. 138–46.

    Google Scholar 

  22. Hadgraft J, Beutner D, Michael Wolff H. In vivo-in vitro comparisons in the transdermal delivery of nitroglycerin. Int J Pharm. 1993;89:R1–4.

    Article  CAS  Google Scholar 

  23. Rohr UD, Altenburger R, Kissel T. Pharmacokinetics of the transdermal reservoir membrane system delivering beta-estradiol: in vitro/in vivo-correlation. Pharm Res. 1998;15:877–82.

    Article  CAS  PubMed  Google Scholar 

  24. Venkateshwaran S. In vitro-in vivo correlation for transdermal delivery. Coronado: IBC International Conference on Transdermal Drug Delivery; 1997. p. 15–16.

  25. Franz TJ, Lehman PA, Raney SG. Use of excised human skin to assess the bioequivalence of topical products. Skin Pharmacol Physiol. 2009;22:276–86.

    Article  CAS  PubMed  Google Scholar 

  26. Franz TJ. Percutaneous absorption on the relevance of in vitro data. J Invest Dermatol. 1975;64:190–5.

    Article  CAS  PubMed  Google Scholar 

  27. Feldmann RJ, Maibach HI. Absorption of some organic compounds through the skin in man. J Invest Dermatol. 1970;54:399–404.

    Article  CAS  PubMed  Google Scholar 

  28. Bronaugh RL, Stewart RF. Methods for in vitro percutaneous absorption studies III: hydrophobic compounds. J Pharm Sci. 1984;73:1255–8.

    Article  CAS  PubMed  Google Scholar 

  29. Scott RC, Ramsey JD. Comparison of the in vivo and in vitro percutaneous absorption of a lipophilic molecule (cypermethrin, a pyrethroid insecticide). J Invest Dermatol. 1987;89:142–6.

    Article  CAS  PubMed  Google Scholar 

  30. Ramsey JD, Woollen BH, Auton TR, Scott RC. The predictive accuracy of in vitro measurements for the dermal absorption of a lipophilic penetrant (fluazifop-butyl) through rat and human skin. Fundam Appl Toxicol. 1994;23:230–6.

    Article  CAS  PubMed  Google Scholar 

  31. US FDA. Guidance for Industry. Nonsterile semisolid dosage forms, scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro release testing and in vivo bioequivalence documentation. Rockville: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 1997.

    Google Scholar 

  32. Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, Fleischer NM, et al. Bioequivalence of topical dermatological dosage forms–methods of evaluation of bioequivalence. Pharm Res. 1998;15:167–71.

    Article  CAS  PubMed  Google Scholar 

  33. Rougier A, Lotte C, Maibach HI. In vivo percutaneous penetration of some organic compounds related to anatomic site in humans: predictive assessment by the stripping method. J Pharm Sci. 1987;76:451–4.

    Article  CAS  PubMed  Google Scholar 

  34. US FDA. Guidance for industry on special protocol assessment. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf (accessed 6/25/2010).

  35. Pershing LK. Bioequivalence assessment of three 0.025% tretinoin gel products: dermatopharmacokinetic vs. clinical trial methods. http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_02_Pershing//index.htm (accessed 6/25/2010).

  36. Franz TJ. Study # 1, avita gel 0.025% vs retin-a gel 0.025%. http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_03_Franz.pdf (accessed 6/25/2010).

  37. Conner DP. Differences in DPK methods. http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_05_conner//index.htm (accessed 6/25/2010).

  38. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295–304.

    Article  CAS  PubMed  Google Scholar 

  39. N’Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res. 2009;26:316–28.

    Article  PubMed  CAS  Google Scholar 

  40. Pershing LK. Final report to Food and Drug Administration (FDA): dermatopharmacokinetic bioequivalence study on three tretinoin gel, 0.025% products. Salt Lake: University of Utah; 2000.

    Google Scholar 

  41. Pershing LK, Nelson JL, Corlett JL, Shrivastava SP, Hare DB, Shah VP. Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J Am Acad Dermatol. 2003;48:740–51.

    Article  PubMed  Google Scholar 

  42. N’Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Optimizing metrics for the assessment of bioequivalence between topical drug products. Pharm Res. 2008;25:1621–30.

    Article  PubMed  CAS  Google Scholar 

  43. Navidi W, Hutchinson A, N’Dri-Stempfer B, Bunge A. Determining bioequivalence of topical dermatological drug products by tape-stripping. J Pharmacokinet Pharmacodyn. 2008;35:337–48.

    Article  PubMed  Google Scholar 

  44. Au WL, Skinner M, Kanfer I. Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations. J Pharm Pharm Sci. 2010;13:11–20.

    CAS  PubMed  Google Scholar 

  45. Kalia YN, Alberti I, Sekkat N, Curdy C, Naik A, Guy RH. Normalization of stratum corneum barrier function and transepidermal water loss in vivo. Pharm Res. 2000;17:1148–50.

    Article  CAS  PubMed  Google Scholar 

  46. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6:429–53.

    Article  CAS  PubMed  Google Scholar 

  47. Russell LM, Wiedersberg S, Delgado-Charro MB. The determination of stratum corneum thickness: an alternative approach. Eur J Pharm Biopharm. 2008;69:861–70.

    Article  CAS  PubMed  Google Scholar 

  48. Pershing LK, Corlett J, Jorgensen C. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrob Agents Chemother. 1994;38:90–5.

    CAS  PubMed  Google Scholar 

  49. Alberti I, Kalia YN, Naik A, Bonny JD, Guy RH. In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum. J Control Release. 2001;71:319–27.

    Article  CAS  PubMed  Google Scholar 

  50. Alberti I, Kalia YN, Naik A, Bonny J, Guy RH. Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int J Pharm. 2001;219:11–9.

    Article  CAS  PubMed  Google Scholar 

  51. Alberti I, Kalia YN, Naik A, Guy RH. Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res. 2001;18:1472–5.

    Article  CAS  PubMed  Google Scholar 

  52. Clarys P, Gabard B, Lambrecht R, Barel A, Bieli E, Ludi S. There is no influence of a temperature rise on in vivo adsorption of UV filters into the stratum corneum. J Dermatol Sci. 2001;27:77–81.

    Article  CAS  PubMed  Google Scholar 

  53. Fernandez C, Nielloud F, Fortune R, Vian L, Marti-Mestres G. Benzophenone-3: rapid prediction and evaluation using non-invasive methods of in vivo human penetration. J Pharm Biomed Anal. 2002;28:57–63.

    Article  CAS  PubMed  Google Scholar 

  54. Wissing SA, Muller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release. 2002;81:225–33.

    Article  CAS  PubMed  Google Scholar 

  55. Jacobi U, Weigmann HJ, Baumann M, Reiche AI, Sterry W, Lademann J. Lateral spreading of topically applied UV filter substances investigated by tape stripping. Skin Pharmacol Physiol. 2004;17:17–22.

    Article  CAS  PubMed  Google Scholar 

  56. Sarveiya V, Risk S, Benson HA. Liquid chromatographic assay for common sunscreen agents: application to in vivo assessment of skin penetration and systemic absorption in human volunteers. J Chromatogr B Anal Technol Biomed Life Sci. 2004;803:225–31.

    Article  CAS  Google Scholar 

  57. Lboutounne H, Chaulet JF, Ploton C, Falson F, Pirot F. Sustained ex vivo skin antiseptic activity of chlorhexidine in poly(epsilon-caprolactone) nanocapsule encapsulated form and as a digluconate. J Control Release. 2002;82:319–34.

    Article  CAS  PubMed  Google Scholar 

  58. Ault JM, Riley CM, Meltzer NM, Lunte CE. Dermal microdialysis sampling in vivo. Pharm Res. 1994;11:1631–9.

    Article  CAS  PubMed  Google Scholar 

  59. Groth L. Cutaneous microdialysis. Methodology and validation. Acta Derm Venereol Suppl (Stockh). 1996;197:1–61.

    CAS  Google Scholar 

  60. Cross SE, Anderson C, Roberts MS. Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies. Br J Clin Pharmacol. 1998;46:29–35.

    Article  CAS  PubMed  Google Scholar 

  61. Benfeldt E. In vivo microdialysis for the investigation of drug levels in the dermis and the effect of barrier perturbation on cutaneous drug penetration. Studies in hairless rats and human subjects. Acta Derm Venereol Suppl (Stockh). 1999;206:1–59.

    CAS  Google Scholar 

  62. Holmgaard R, Nielsen JB, Benfeldt E. Microdialysis sampling for investigations of bioavailability and bioequivalence of topically administered drugs: current state and future perspectives. Skin Pharmacol Physiol. 2010;23:225–43.

    Article  CAS  PubMed  Google Scholar 

  63. Schmidt S, Banks R, Kumar V, Rand KH, Derendorf H. Clinical microdialysis in skin and soft tissues: an update. J Clin Pharmacol. 2008;48:351–64.

    Article  CAS  PubMed  Google Scholar 

  64. Benfeldt E, Bashaw ED, Shah VP. In: Walters K, Roberts MS, editors. Assessment of topical bioequivalence using microdialysis and other techniques. New York: Taylor & Francis; 2007. p. 537–48.

    Google Scholar 

  65. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, et al. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res. 2007;24:1014–25.

    Article  CAS  PubMed  Google Scholar 

  66. Fulzele SV, Babu RJ, Ahaghotu E, Singh M. Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals. Toxicology. 2007;237:77–88.

    Article  CAS  PubMed  Google Scholar 

  67. Teichmann A, Otberg N, Jacobi U, Sterry W, Lademann J. Follicular penetration: development of a method to block the follicles selectively against the penetration of topically applied substances. Skin Pharmacol Physiol. 2006;19:216–23.

    Article  CAS  PubMed  Google Scholar 

  68. McCleverty D, Lyons R, Henry B. Microdialysis sampling and the clinical determination of topical dermal bioequivalence. Int J Pharm. 2006;308:1–7.

    Article  CAS  PubMed  Google Scholar 

  69. Benfeldt E, Hansen SH, Volund A, Menne T, Shah VP. Bioequivalence of topical formulations in humans: evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J Invest Dermatol. 2007;127:170–8.

    Article  CAS  PubMed  Google Scholar 

  70. Carneheim C, Stahle L. Microdialysis of lipophilic compounds: a methodological study. Pharmacol Toxicol. 1991;69:378–80.

    Article  CAS  PubMed  Google Scholar 

  71. Ward KW, Medina SJ, Portelli ST, Mahar Doan KM, Spengler MD, Ben MM, et al. Enhancement of in vitro and in vivo microdialysis recovery of SB-265123 using Intralipid and Encapsin as perfusates. Biopharm Drug Dispos. 2003;24:17–25.

    Article  CAS  PubMed  Google Scholar 

  72. Sun L, Stenken JA. Improving microdialysis extraction efficiency of lipophilic eicosanoids. J Pharm Biomed Anal. 2003;33:1059–71.

    Article  CAS  PubMed  Google Scholar 

  73. Groth L, Garcia OP, Benfeldt E. Microdialysis methodology for sampling in the skin. In: Serup J, Jemec GBE, Grove GL, editors. Handbook of non-invasive methods and the skin. Boca Raton: Taylor & Francis; 2006. p. 443–54.

    Google Scholar 

  74. Plock N, Kloft C. Microdialysis–theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci. 2005;25:1–24.

    Article  CAS  PubMed  Google Scholar 

  75. Kellogg Jr DL, Zhao JL, Wu Y. Neuronal nitric oxide synthase control mechanisms in the cutaneous vasculature of humans in vivo. J Physiol. 2008;586:847–57.

    Article  CAS  PubMed  Google Scholar 

  76. Tettey-Amlalo RN, Kanfer I, Skinner MF, Benfeldt E, Verbeeck RK. Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel. Eur J Pharm Sci. 2009;36:219–25.

    Article  CAS  PubMed  Google Scholar 

  77. Ortiz PG, Hansen SH, Shah VP, Menne T, Benfeldt E. The effect of irritant dermatitis on cutaneous bioavailability of a metronidazole formulation, investigated by microdialysis and dermatopharmacokinetic method. Contact Dermat. 2008;59:23–30.

    Article  CAS  Google Scholar 

  78. Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: an overview. Skin Pharmacol Physiol. 2007;20:272–82.

    Article  PubMed  Google Scholar 

  79. Trommer H, Neubert RH. Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol Physiol. 2006;19:106–21.

    Article  CAS  PubMed  Google Scholar 

  80. Korinth G, Jakasa I, Wellner T, Kezic S, Kruse J, Schaller KH. Percutaneous absorption and metabolism of 2-butoxyethanol in human volunteers: a microdialysis study. Toxicol Lett. 2007;170:97–103.

    Article  CAS  PubMed  Google Scholar 

  81. Brunner M, Dehghanyar P, Seigfried B, Martin W, Menke G, Muller M. Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. Br J Clin Pharmacol. 2005;60:573–7.

    Article  CAS  PubMed  Google Scholar 

  82. Mathy FX, Ntivunwa D, Verbeeck RK, Preat V. Fluconazole distribution in rat dermis following intravenous and topical application: a microdialysis study. J Pharm Sci. 2005;94:770–80.

    Article  CAS  PubMed  Google Scholar 

  83. Klimowicz A, Farfal S, Bielecka-Grzela S. Evaluation of skin penetration of topically applied drugs in humans by cutaneous microdialysis: acyclovir vs. salicylic acid. J Clin Pharm Ther. 2007;32:143–8.

    Article  CAS  PubMed  Google Scholar 

  84. Garcia Ortiz P, Hansen SH, Shah VP, Menne T, Benfeldt E. Impact of adult atopic dermatitis on topical drug penetration: assessment by cutaneous microdialysis and tape stripping. Acta Derm Venereol. 2009;89:33–8.

    CAS  PubMed  Google Scholar 

  85. Kezic S. Methods for measuring in-vivo percutaneous absorption in humans. Hum Exp Toxicol. 2008;27:289–95.

    Article  CAS  PubMed  Google Scholar 

  86. Zhao J, Lui H, McLean DI, Zeng H. Integrated real-time Raman system for clinical in vivo skin analysis. Skin Res Technol. 2008;14:484–92.

    Article  PubMed  Google Scholar 

  87. Crowther JM, Sieg A, Blenkiron P, Marcott C, Matts PJ, Kaczvinsky JR, et al. Measuring the effects of topical moisturizers on changes in stratum corneum thickness, water gradients and hydration in vivo. Br J Dermatol. 2008;159:567–77.

    CAS  PubMed  Google Scholar 

  88. Caussin J, Rozema E, Gooris GS, Wiechers JW, Pavel S, Bouwstra JA. Hydrophilic and lipophilic moisturizers have similar penetration profiles but different effects on SC water distribution in vivo. Exp Dermatol. 2009;18:954–61.

    Article  CAS  PubMed  Google Scholar 

  89. Darlenski R, Sassning S, Tsankov N, Fluhr JW. Non-invasive in vivo methods for investigation of the skin barrier physical properties. Eur J Pharm Biopharm. 2009;72:295–303.

    Article  CAS  PubMed  Google Scholar 

  90. Caspers PJ, Williams AC, Carter EA, Edwards HG, Barry BW, Bruining HA, et al. Monitoring the penetration enhancer dimethyl sulfoxide in human stratum corneum in vivo by confocal Raman spectroscopy. Pharm Res. 2002;19:1577–80.

    Article  CAS  PubMed  Google Scholar 

  91. Wascotte V, Caspers P, de Sterke J, Jadoul M, Guy RH, Preat V. Assessment of the “skin reservoir” of urea by confocal Raman microspectroscopy and reverse iontophoresis in vivo. Pharm Res. 2007;24:1897–901.

    Article  CAS  PubMed  Google Scholar 

  92. Pudney PD, Melot M, Caspers PJ, Van Der Pol A, Puppels GJ. An in vivo confocal Raman study of the delivery of trans retinol to the skin. Appl Spectrosc. 2007;61:804–11.

    Article  CAS  PubMed  Google Scholar 

  93. Melot M, Pudney PD, Williamson AM, Caspers PJ, Van Der Pol A, Puppels GJ. Studying the effectiveness of penetration enhancers to deliver retinol through the stratum cornum by in vivo confocal Raman spectroscopy. J Control Release. 2009;138:32–9.

    Article  CAS  PubMed  Google Scholar 

  94. Pirot F, Kalia YN, Stinchcomb AL, Keating G, Bunge A, Guy RH. Characterization of the permeability barrier of human skin in vivo. Proc Natl Acad Sci USA. 1997;94:1562–7.

    Article  CAS  PubMed  Google Scholar 

  95. Stinchcomb AL, Pirot F, Touraille GD, Bunge AL, Guy RH. Chemical uptake into human stratum corneum in vivo from volatile and non-volatile solvents. Pharm Res. 1999;16:1288–93.

    Article  CAS  PubMed  Google Scholar 

  96. Reddy MB, Stinchcomb AL, Guy RH, Bunge AL. Determining dermal absorption parameters in vivo from tape strip data. Pharm Res. 2002;19:292–8.

    Article  CAS  PubMed  Google Scholar 

  97. Medendorp J, Yedluri J, Hammell DC, Ji T, Lodder RA, Stinchcomb AL. Near-infrared spectrometry for the quantification of dermal absorption of econazole nitrate and 4-cyanophenol. Pharm Res. 2006;23:835–43.

    Article  CAS  PubMed  Google Scholar 

  98. Medendorp JP, Paudel KS, Lodder RA, Stinchcomb AL. Near infrared spectrometry for the quantification of human dermal absorption of econazole nitrate and estradiol. Pharm Res. 2007;24:186–93.

    Article  CAS  PubMed  Google Scholar 

  99. Egawa M. In vivo simultaneous measurement of urea and water in the human stratum corneum by diffuse-reflectance near-infrared spectroscopy. Skin Res Technol. 2009;15:195–9.

    Article  PubMed  Google Scholar 

  100. Thilwind RE, ‘t Hooft G, Uzunbajakava NE. Improved depth resolution in near-infrared diffuse reflectance spectroscopy using obliquely oriented fibers. J Biomed Opt. 2009;14:024026.

    Article  PubMed  Google Scholar 

  101. Bhandari M, Lochner H, Tornetta 3rd P. Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small. Arch Orthop Trauma Surg. 2002;122:96–8.

    Article  PubMed  Google Scholar 

  102. Donner A, Eliasziw M. Statistical implications of the choice between a dichotomous or continuous trait in studies of interobserver agreement. Biometrics 1994;50:550–5.

    Article  CAS  PubMed  Google Scholar 

  103. Bunge AL, Guy RH. Dermatopharmacokinetics: improvement of methodology for assessing bioequivalence of topical products: Presentation to FDA advisory committee for pharmaceutical science, October 2003. FDA 2003. http://www.fda.gov/ohrms/dockets/ac/03/slides/3996S2_07_Bunge.pdf. (accessed 7/31/2010).

  104. Russell LM, Guy RH. Measurement and prediction of the rate and extent of drug delivery into and through the skin. Expert Opin Drug Deliv. 2009;6:355–69.

    Article  CAS  PubMed  Google Scholar 

  105. Johansson J, Lahti A. Topical non-steroidal anti-inflammatory drugs inhibit non-immunologic immediate contact reactions. Contact Dermat. 1988;19:161–5.

    Article  CAS  Google Scholar 

  106. Poelman MC, Piot B, Guyon F, Deroni M, Leveque JL. Assessment of topical non-steroidal anti-inflammatory drugs. J Pharm Pharmacol. 1989;41:720–2.

    CAS  PubMed  Google Scholar 

  107. Duteil L, Queille C, Poncet M, Ortonne JP, Czernielewski J. Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation. Clin Exp Dermatol. 1990;15:195–9.

    Article  CAS  PubMed  Google Scholar 

  108. Chan SY, Li Wan Po A. Quantitative evaluation of drug-induced erythema by using a tristimulus colour analyzer: experimental design and data analysis. Skin Pharmacol. 1993;6:298–312.

    Article  CAS  PubMed  Google Scholar 

  109. Treffel P, Gabard B. Feasibility of measuring the bioavailability of topical ibuprofen in commercial formulations using drug content in epidermis and a methyl nicotinate skin inflammation assay. Skin Pharmacol. 1993;6:268–75.

    Article  CAS  PubMed  Google Scholar 

  110. Tagami H, Tadaki T, Obata M, Koyama J. Functional assessment of the stratum corneum under the influence of oral aromatic retinoid (etretinate) in guinea-pigs and humans. Comparison with topical retinoic acid treatment. Br J Dermatol. 1992;127:470–5.

    Article  CAS  PubMed  Google Scholar 

  111. Fluhr JW, Vienne MP, Lauze C, Dupuy P, Gehring W, Gloor M. Tolerance profile of retinol, retinaldehyde and retinoic acid under maximized and long-term clinical conditions. Dermatology. 1999;199 Suppl 1:57–60.

    Article  CAS  PubMed  Google Scholar 

  112. Verschoore M, Poncet M, Czernielewski J, Sorba V, Clucas A. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol. 1997;36:S104–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Actavis Mid-Atlantic LLC, Product Development, 10065 Red Run Blvd., Owings Mills, Maryland, 21117, USA

    Yogeeta Narkar

Authors
  1. Yogeeta Narkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yogeeta Narkar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Narkar, Y. Bioequivalence for Topical Products—An Update. Pharm Res 27, 2590–2601 (2010). https://doi.org/10.1007/s11095-010-0250-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-010-0250-3

KEY WORDS

Search

Navigation